Adaptive Biotechnologies (ADPT) Receivables - Net (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Receivables - Net data on file, last reported at $48.3 million in Q1 2026.

• Quarterly Receivables - Net rose 10.86% year-over-year to $48.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.3 million (up 10.86% YoY) and the FY2025 annual result came in at $50.4 million, up 20.69% from the prior year.
• Receivables - Net retreated to $48.3 million in Q1 2026 per ADPT's latest filing, from $50.4 million in the prior quarter.
• The five-year high for Receivables - Net was $50.4 million in Q4 2025, with the low at $22.5 million in Q1 2022.
• Average Receivables - Net over 5 years is $37.4 million, with a median of $40.1 million recorded in 2022.
• Year-over-year, Receivables - Net soared 130.09% in 2022 and decreased 5.21% in 2023.
• Adaptive Biotechnologies' Receivables - Net stood at $40.1 million in 2022, then decreased by 5.21% to $38.0 million in 2023, then rose by 9.91% to $41.7 million in 2024, then climbed by 20.69% to $50.4 million in 2025, then slipped by 4.07% to $48.3 million in 2026.
• Business Quant data shows ADPT's Receivables - Net at $48.3 million in Q1 2026, $50.4 million in Q4 2025, and $44.8 million in Q3 2025.